McDermott Advises DBV Technologies In Connection With Its $81 Million Capital Increase

Overview


McDermott Will & Emery assisted DBV Technologies, a French biopharmaceutical company, in its $81 million capital increase. Its common shares were offered in the United States in the form of American Depositary Shares, traded on the Nasdaq Select Global Market. Concurrently, common shares were sold in Europe in a private placement and are traded on the Euronext Paris. This fundraising will assist in financing the development and preparation for the commercialization of its anti-peanut allergy patch, Viaskin Peanut (subject to approval by regulatory authorities), as well as in advancing the development of its sister projects.

McDermott Will & Emery assisted DBV Technologies with a team led by Emmanuelle Trombe and Bertrand Delafaye, Partners, and including Mathilde Peschard, Laetitia de Dinechin and Baptiste Tigaud on corporate issues, as well as Partner Antoine Vergnat and Côme de Saint-Vincent on the tax aspects.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective – and often unexpected – solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts